Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.

January 17, 2025

Vol.51 No.02

Clinical Roundup

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Drug in clinical trials for breast cancer could also treat some blood cancers, studies show

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

December 13, 2024

Vol.50 No.46

In Brief

Krish Patel joins Sarah Cannon as director of lymphoma research

Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

November 22, 2024

Vol.50 No.44

Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

YOU MAY BE INTERESTED IN

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

Drug in clinical trials for breast cancer could also treat some blood cancers, studies show

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Krish Patel joins Sarah Cannon as director of lymphoma research

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

Renew today!

Subscriber content

Never miss an issue!

Login